Skip to main content

Table 5 Radioimmunotherapy for recurrent SCCHN receiving re-RT

From: Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience

Re-RT (21 pts, 1 pt treated for bone metastases)

   

IMRT

16/22 pts

   

3D-RT

3/22 pts

   

conventional RT

3/22 pts

   

prior RT

Dose (Gy)

time between RT treatments (months)

cumulative Dose (Gy)

 

median

66

83,5

106,4

 

min

40

17

96

 

max

70,4

293

125,6

Re-RT

    
 

median

45

  
 

min

34,2

  
 

max

59,6

  

response (21 pts)

   

CR

2 pts

  

PR

10 pts

  

SD

2 pts

  

PD

5 pts

  

dna

1 pt

  

f/u unavailable

1 pt